DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Invest...
January 07 2017 - 6:00AM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Southern
District of New York on behalf of purchasers of Alexion
Pharmaceuticals, Inc. (Nasdaq: ALXN) (“Alexion” or the “Company”)
securities during the period between February 10, 2014 and November
9, 2016, inclusive (the “Class Period”). Investors who wish to
become proactively involved in the litigation have until January
17, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Alexion securities during the Class Period. Members
of the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. No class has yet been certified in
the above action.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that Alexion employed
improper sales practices with respect to Soloris, a monoclonal
antibody for the treatment of paroxysmal nocturnal hemoglobinuria
(“PNH”) and atypical hemolytic uremic syndrome (“aHUS”), and the
Company’s revenues from Soloris sales were unlikely to be
sustainable.
According to the complaint, following a November 4, 2016
cancellation of an appearance at the Credit Suisse Healthcare
Conference and a failure to file its Quarterly Report with the U.S.
Securities and Exchange Commission within two days of its earnings
announcement, and a November 9, 2016 press release, Form 8-K, and
Form NT 10-Q announcing that it would not be able to timely file
its financial and operating results for the quarter ended September
30, 2016 because the Company was conducting an investigation into
allegations regarding sales practices of Soloris, the value of
Alexion shares declined significantly.
If you have suffered a loss in excess of $100,000 from
investment in Alexion securities purchased on or after February 10,
2014 and held through the revelation of negative information during
and/or at the end of the Class Period and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Brower Piven also encourages anyone with information
regarding the Company’s conduct during the period in question to
contact the firm, including whistleblowers, former employees,
shareholders and others.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170107005020/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024